Basaglar (insulin glargine) is a brand-name subcutaneous injection that’s prescribed for managing blood sugar levels in certain people. As with other drugs, Basaglar can cause side effects, such as ...

The follow-on or copycat insulin glargine product Basaglar (Lilly) is similar to brand-name Lantus (Sanofi) in terms of efficacy and safety for the treatment of type 2 diabetes, but Basaglar cost less ...

Basaglar (insulin glargine) and Lantus (insulin glargine) are brand-name prescription medications. They’re approved by the Food and Drug Administration (FDA) to: improve blood sugar levels in adults ...

The FDA has granted tentative approval for Basaglar (insulin glargine injection), produced by Eli Lilly and Boehringer Ingelheim's (BI) diabetes alliance, following litigation filed by Sanofi claiming ...

Basaglar is a brand-name prescription drug that can help people with diabetes manage their blood sugar levels. It contains the active drug insulin glargine, a long-acting form of insulin. Also called ...

The U.S. Food and Drug Administration today approved Basaglar (insulin glargine injection), a long-acting human insulin analog to improve glycemic control in adult and pediatric patients with type 1 ...

The U.S. Food and Drug Administration on Wednesday approved Eli Lilly & Co's diabetes drug Basaglar, a cheaper version of Sanofi AG's top-selling drug Lantus. The drug, an injection known also as ...

Eli Lilly and Boehringer Ingelheim announced the launch of Basaglar (insulin glargine injection) for use to control high blood sugar in children and adults with type 1 diabetes and adults with type 2 ...

FDA Issues Complete Response Letter for Diabetes Drug The FDA has approved Basaglar (insulin glargine; Eli Lilly and Boehringer Ingelheim) injection to improve glycemic control in pediatric patients ...

If you have diabetes, your doctor might suggest Basaglar (insulin glargine) as a treatment option for you. It’s a prescription drug used to treat: type 1 diabetes in adults and children ages 6 years ...

Original Medicare (parts A and B) typically doesn’t cover Basaglar, an insulin glargine medication, but Medicare Advantage (Part C) and Part D plans may offer coverage depending on their specific ...